• Explore /
  • Poster
  • / A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).

A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Munjid Al Harthy

NCI/NIH, Bethesda, MD

Munjid Al Harthy , Ravi Amrit Madan , Fatima Karzai , Daniel Peter Petrylak , Joseph W. Kim , Philip M. Arlen , Marc Robert Theoret , Jenn Marte , Marijo Bilusic , Anna Couvillon , Guinevere Chun , Helen Owens , Amy Hankin , Lisa M. Cordes , William Douglas Figg , James L. Gulley , William L. Dahut

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01683994

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 173)

DOI

10.1200/JCO.2019.37.7_suppl.173

Abstract #

173

Poster Bd #

G16

Abstract Disclosures

Similar Posters

First Author: Fatima H. Karzai

First Author: Reeta Barua

First Author: Christophe Massard

First Author: Christophe Massard